MicroRNA-137 and microRNA-195* inhibit vasculogenesis in brain arteriovenous malformations

Jun Huang1,2, Jianping Song3, Meijie Qu2

  • 1Shanghai Key Laboratory of Hypertension, Department of Hypertension, Ruijin Hospital and Shanghai Institute of Hypertension, Shanghai JiaoTong University School of Medicine, Shanghai, China.

Annals of Neurology
|August 13, 2017
PubMed
Abstract

Insights

Reduced expression of miR-137 and miR-195* contributes to brain arteriovenous malformations (AVMs). Restoring these microRNAs (miRNAs) inhibits abnormal blood vessel formation, suggesting a therapeutic target for AVMs.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Brain arteriovenous malformations (AVMs) are a leading cause of intracerebral hemorrhage in young adults.
  • The exact mechanisms underlying AVM development remain largely unknown.
  • MicroRNA (miRNA) dysregulation is implicated in various vascular diseases.

Purpose of the Study:

  • To investigate the role of miRNA expression in the pathogenesis of brain AVMs.
  • To identify specific miRNAs associated with AVM development.
  • To elucidate the functional impact of identified miRNAs on AVM cells.

Main Methods:

  • Large-scale miRNA profiling of AVM samples, hemangioblastoma, and controls.
  • Isolation and characterization of AVM smooth muscle cells (AVMSMCs).
  • In vitro assays (migration, tube formation, proliferation) and in vivo vascular ring formation assays to assess miRNA function.
  • Quantitative proteomics to identify downstream protein targets of key miRNAs.

Main Results:

  • A distinct miRNA signature for AVMs was identified, characterized by decreased expression of several miRNAs.
  • miR-137 and miR-195* levels were significantly reduced in AVMs and AVMSMCs.
  • Experimental restoration of miR-137 and miR-195* inhibited AVMSMC migration, tube formation, survival, and vascular ring formation.
  • Proteomic analysis revealed downstream signaling proteins involved in vessel development regulated by these miRNAs.

Conclusions:

  • miR-137 and miR-195* function as vasculogenic suppressors in AVMs.
  • The downregulation of these miRNAs contributes to abnormal blood vessel development in AVMs.
  • These findings highlight the potential of targeting miR-137 and miR-195* for AVM treatment.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.2K